PCI Biotech: Utøvelse av opsjoner

July 01, 2013 02:00 ET | Source: PCI Biotech Holding ASA PCI Biotech Holding ASA

Primærinnsider i PCI Biotech Holding ASA Bernt-Olav Røttingsnes (CFO) har 28. juni 2013 utøvet 60.000 opsjoner tildelt 22. juni 2009. Utøvelseskurs for opsjonene er 6,47 kroner. Etter opsjonsutøvelsen har Bernt-Olav Røttingsnes 60.000 aksjer i PCI Biotech Holding ASA.

This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Recommended Reading

January 29, 2026 11:50 ET | Source: PCI Biotech Holding ASA

PCI Biotech initiates a process to evaluate the opportunity for a structured wind-up process

Oslo (Norway), 29 January 2026 – PCI Biotech (OSE: PCIB) refers to its latest announcement of 8 January 2026 regarding the discontinuation of all R&D operations and the continued exploration of...
Read More
January 08, 2026 08:10 ET | Source: PCI Biotech Holding ASA

PCI Biotech announces discontinuation of R&D operations and continues evaluation of future options

Oslo (Norway), 8 January 2026 – PCI Biotech (OSE: PCIB). Reference is made to the company’s latest announcement dated 23rd October 2025. The external evaluation of a new bioprocessing technology has...
Read More